AU2007246144B2 - Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK - Google Patents

Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK Download PDF

Info

Publication number
AU2007246144B2
AU2007246144B2 AU2007246144A AU2007246144A AU2007246144B2 AU 2007246144 B2 AU2007246144 B2 AU 2007246144B2 AU 2007246144 A AU2007246144 A AU 2007246144A AU 2007246144 A AU2007246144 A AU 2007246144A AU 2007246144 B2 AU2007246144 B2 AU 2007246144B2
Authority
AU
Australia
Prior art keywords
seq
antibody
sequence
alk
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007246144A
Other languages
English (en)
Other versions
AU2007246144A1 (en
Inventor
Adrian Auf Der Maur
Alcide Barberis
Peter Lichtlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delenex Therapeutics AG
Original Assignee
Delenex Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delenex Therapeutics AG filed Critical Delenex Therapeutics AG
Publication of AU2007246144A1 publication Critical patent/AU2007246144A1/en
Assigned to DELENEX THERAPEUTICS AG reassignment DELENEX THERAPEUTICS AG Request for Assignment Assignors: ESBATECH AG
Priority to AU2012244351A priority Critical patent/AU2012244351B2/en
Application granted granted Critical
Publication of AU2007246144B2 publication Critical patent/AU2007246144B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007246144A 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK Ceased AU2007246144B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012244351A AU2012244351B2 (en) 2006-04-28 2012-11-02 Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79583106P 2006-04-28 2006-04-28
US60/795,831 2006-04-28
PCT/CH2007/000202 WO2007124610A1 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012244351A Division AU2012244351B2 (en) 2006-04-28 2012-11-02 Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Publications (2)

Publication Number Publication Date
AU2007246144A1 AU2007246144A1 (en) 2007-11-08
AU2007246144B2 true AU2007246144B2 (en) 2012-12-06

Family

ID=38515389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007246144A Ceased AU2007246144B2 (en) 2006-04-28 2007-04-27 Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Country Status (16)

Country Link
US (3) US7902340B2 (enExample)
EP (2) EP2013236B1 (enExample)
JP (2) JP5431920B2 (enExample)
KR (1) KR101457228B1 (enExample)
CN (1) CN101443361B (enExample)
AU (1) AU2007246144B2 (enExample)
BR (1) BRPI0710971A2 (enExample)
CA (1) CA2650822C (enExample)
DK (1) DK2013236T3 (enExample)
ES (1) ES2547248T3 (enExample)
IL (1) IL194752A0 (enExample)
MX (1) MX2008013705A (enExample)
NZ (1) NZ572248A (enExample)
PL (1) PL2013236T3 (enExample)
RU (1) RU2460540C2 (enExample)
WO (1) WO2007124610A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101443361B (zh) * 2006-04-28 2015-08-19 德勒尼克斯治疗股份公司 与受体酪氨酸激酶alk的胞外域结合的抗体
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
SI2752428T1 (sl) 2008-06-25 2020-03-31 Novartis Ag Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa
AU2009264564B2 (en) 2008-06-25 2014-05-08 Novartis Ag Stable and soluble antibodies inhibiting TNFalpha
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
HK1199883A1 (en) 2011-08-26 2015-07-24 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2013067492A1 (en) * 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
CN104861069B (zh) * 2014-02-21 2018-12-18 无锡傲锐东源生物科技有限公司 针对间变性淋巴瘤激酶的单克隆抗体1a4及其用途
US20170100428A1 (en) * 2014-05-30 2017-04-13 Kolltan Pharmaceuticals, Inc. Regulators of anaplastic lymphoma kinase and uses thereof
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
CA2940470C (en) 2015-09-18 2019-08-20 Signpath Pharma Inc. Treatment for glioblastoma
MX2018004515A (es) * 2015-10-13 2019-04-15 Eureka Therapeutics Inc Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
CN107614519B (zh) 2015-10-23 2022-08-05 优瑞科生物技术公司 抗体/t细胞受体嵌合构建体及其用途
WO2017147408A1 (en) * 2016-02-25 2017-08-31 The Regents Of The University Of California Methods for the treatment of hematologic cancer
JP7538601B2 (ja) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
AU2019216761B2 (en) * 2018-02-09 2025-04-10 Acceleron Pharma Inc. Methods for treating heterotopic ossification
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN113960313B (zh) * 2021-12-22 2022-04-12 上海思路迪医学检验所有限公司 一种外泌体alk融合蛋白磁免疫化学发光检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21505A (en) * 1858-09-14 Improvement in bullet-machines
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
ATE253593T1 (de) 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
JPH1116250A (ja) * 1997-06-20 1999-01-22 Pioneer Electron Corp 情報再生システム
DK1242457T3 (da) * 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
ATE460427T1 (de) 2000-06-14 2010-03-15 Univ Georgetown Pleiotrophin wachstumfaktor rezeptor alk zur behandlung von proliferativen, gefässer- und neurologischen erkrankungen
ES2335861T3 (es) 2000-09-08 2010-04-06 Universitat Zurich Grupos de proteinas repetitivas que comprenden modulos repetitivos.
US8853362B2 (en) * 2002-05-22 2014-10-07 Esbatech, An Alcon Biomedical Research Unit Llc Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US7888485B2 (en) 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
WO2006020684A2 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
CN101443361B (zh) * 2006-04-28 2015-08-19 德勒尼克斯治疗股份公司 与受体酪氨酸激酶alk的胞外域结合的抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Stoica, G. E. et al. Journal of Biological Chemistry (2002) Vol. 277, No. 39, pages 35990-35998 *

Also Published As

Publication number Publication date
KR20080113261A (ko) 2008-12-29
CN101443361A (zh) 2009-05-27
JP2013226144A (ja) 2013-11-07
IL194752A0 (en) 2011-08-01
MX2008013705A (es) 2008-11-06
US20150203829A1 (en) 2015-07-23
BRPI0710971A2 (pt) 2011-05-31
JP5911821B2 (ja) 2016-04-27
EP2013236B1 (en) 2015-06-17
US7902340B2 (en) 2011-03-08
CA2650822A1 (en) 2007-11-08
EP2604627A1 (en) 2013-06-19
JP2009535021A (ja) 2009-10-01
US8945563B2 (en) 2015-02-03
WO2007124610A1 (en) 2007-11-08
US9512411B2 (en) 2016-12-06
DK2013236T3 (en) 2015-09-21
CA2650822C (en) 2017-03-14
AU2007246144A1 (en) 2007-11-08
HK1124619A1 (en) 2009-07-17
NZ572248A (en) 2011-08-26
US20110159008A1 (en) 2011-06-30
EP2013236A1 (en) 2009-01-14
RU2460540C2 (ru) 2012-09-10
CN101443361B (zh) 2015-08-19
JP5431920B2 (ja) 2014-03-05
KR101457228B1 (ko) 2014-11-04
ES2547248T3 (es) 2015-10-02
RU2008146922A (ru) 2010-06-10
PL2013236T3 (pl) 2015-12-31
US20080118512A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
AU2007246144B2 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
KR102037016B1 (ko) 항 pd-l1 나노 항체 및 이의 응용
JP7336122B2 (ja) 抗ｖｅｇｆ単一ドメイン抗体およびその応用
US20230416379A1 (en) ALK7 Binding Proteins and Uses Thereof
TW201609812A (zh) 最佳化之跨物種特異性雙特異性單鏈抗體構築體
IL303474A (en) Anti-TSLP nanobodies and their applications
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
KR20220160670A (ko) 항 pd-l1 및 pd-l2 항체 및 이의 유도체 및 용도
CN111825766B (zh) 抗il-4r单域抗体及其应用
JP7617036B2 (ja) Ａｌｋ７結合タンパク質及びその使用
WO2008131575A2 (en) Anti-alk antibodies suitable for treating metastatic cancers or tumors
AU2012244351B2 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK
US20240101663A1 (en) Method for inhibiting tumour cell growth based on ccdc112
CN111108120A (zh) 抗人类血管内皮生长因子受体的抗体及其应用
HK1124619B (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
HK40060753B (zh) 对muc18特异性的抗体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DELENEX THERAPEUTICS AG

Free format text: FORMER APPLICANT(S): ESBATECH AG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired